PE20240636A1 - Combinaciones farmaceuticas para el tratamiento del cancer - Google Patents
Combinaciones farmaceuticas para el tratamiento del cancerInfo
- Publication number
- PE20240636A1 PE20240636A1 PE2023002648A PE2023002648A PE20240636A1 PE 20240636 A1 PE20240636 A1 PE 20240636A1 PE 2023002648 A PE2023002648 A PE 2023002648A PE 2023002648 A PE2023002648 A PE 2023002648A PE 20240636 A1 PE20240636 A1 PE 20240636A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer
- treatment
- pharmaceutical combinations
- icm
- progression
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940123309 Immune checkpoint modulator Drugs 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invencion se refiere a una combinacion farmaceutica que comprende una cepa bacteriana gramnegativa recombinante y un modulador de puntos de control inmunologico (ICM) y su uso en un metodo para la prevencion, el retraso de la progresion o el tratamiento del cancer en un sujeto
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21164882 | 2021-03-25 | ||
PCT/EP2022/057752 WO2022200493A1 (en) | 2021-03-25 | 2022-03-24 | Pharmaceutical combinations for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240636A1 true PE20240636A1 (es) | 2024-03-27 |
Family
ID=75362326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023002648A PE20240636A1 (es) | 2021-03-25 | 2022-03-24 | Combinaciones farmaceuticas para el tratamiento del cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20240165265A1 (es) |
EP (1) | EP4313310A1 (es) |
JP (1) | JP2024511096A (es) |
KR (1) | KR20230160895A (es) |
CN (1) | CN117440829A (es) |
AU (1) | AU2022244124A1 (es) |
BR (1) | BR112023019473A2 (es) |
CA (1) | CA3210774A1 (es) |
CL (1) | CL2023002812A1 (es) |
CO (1) | CO2023012667A2 (es) |
IL (1) | IL305974A (es) |
MX (1) | MX2023010989A (es) |
PE (1) | PE20240636A1 (es) |
WO (1) | WO2022200493A1 (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002077249A2 (en) | 2001-03-26 | 2002-10-03 | Universite Catholique De Louvain | Type iii bacterial strains for use in medicine |
EP3331554B1 (en) * | 2015-08-03 | 2022-05-11 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
HUE051184T2 (hu) * | 2015-11-19 | 2021-03-01 | Univ Basel | Baktériumalapú fehérjeszállítás |
PT3559022T (pt) * | 2016-12-20 | 2021-08-19 | Univ Basel | Distribuição de proteínas baseada em bactérias com virulência atenuada |
WO2018136617A2 (en) * | 2017-01-18 | 2018-07-26 | Evelo Biosciences, Inc. | Methods of treating cancer |
-
2022
- 2022-03-24 CN CN202280036608.2A patent/CN117440829A/zh active Pending
- 2022-03-24 US US18/551,502 patent/US20240165265A1/en active Pending
- 2022-03-24 BR BR112023019473A patent/BR112023019473A2/pt unknown
- 2022-03-24 MX MX2023010989A patent/MX2023010989A/es unknown
- 2022-03-24 IL IL305974A patent/IL305974A/en unknown
- 2022-03-24 EP EP22717802.7A patent/EP4313310A1/en active Pending
- 2022-03-24 WO PCT/EP2022/057752 patent/WO2022200493A1/en active Application Filing
- 2022-03-24 AU AU2022244124A patent/AU2022244124A1/en active Pending
- 2022-03-24 PE PE2023002648A patent/PE20240636A1/es unknown
- 2022-03-24 JP JP2023558268A patent/JP2024511096A/ja active Pending
- 2022-03-24 KR KR1020237036531A patent/KR20230160895A/ko unknown
- 2022-03-24 CA CA3210774A patent/CA3210774A1/en active Pending
-
2023
- 2023-09-21 CL CL2023002812A patent/CL2023002812A1/es unknown
- 2023-09-25 CO CONC2023/0012667A patent/CO2023012667A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL305974A (en) | 2023-11-01 |
AU2022244124A1 (en) | 2023-11-09 |
US20240165265A1 (en) | 2024-05-23 |
CO2023012667A2 (es) | 2023-09-29 |
CA3210774A1 (en) | 2022-09-29 |
KR20230160895A (ko) | 2023-11-24 |
MX2023010989A (es) | 2023-09-27 |
CN117440829A (zh) | 2024-01-23 |
AU2022244124A9 (en) | 2023-11-16 |
BR112023019473A2 (pt) | 2023-12-05 |
CL2023002812A1 (es) | 2024-04-05 |
JP2024511096A (ja) | 2024-03-12 |
EP4313310A1 (en) | 2024-02-07 |
WO2022200493A1 (en) | 2022-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020016559A2 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
CL2019000277A1 (es) | Tratamiento conjunto contra el cáncer. | |
BR112018013995A2 (pt) | terapia de combinação de vírus oncolítico e inibidor de ponto de verificação | |
BR112018077266A2 (pt) | composições compreendendo cepas bacterianas | |
CO2017013231A2 (es) | Composiciones que comprenden una cepa bacteriana del género parabacteroides | |
CO2017013287A2 (es) | Composiciones que comprenden una cepa bacteriana del género roseburia | |
CY1124488T1 (el) | Απελευθερωση πρωτεϊνης που βασιζεται σε εξασθενημενης λοιμογονικοτητας βακτηριδια | |
CL2018000853A1 (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer. | |
CL2023002105A1 (es) | Dominios variables de anticuerpo que se dirigen a cd33 y sus usos | |
ES2692773T3 (es) | Tratamientos para la fibrosis | |
BR112016024352A2 (pt) | ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria? | |
CA3060516A1 (en) | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy | |
CL2016002794A1 (es) | Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico | |
CO2020010013A2 (es) | Terapia de combinación para tratar o prevenir el cáncer | |
CO2021017317A2 (es) | Células seguras e invisibles para el sistema inmunitario | |
BR112022005687A2 (pt) | Vacinas contra o hbv e métodos para tratar o hbv | |
CL2018002793A1 (es) | Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control | |
CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
BR112016015078A2 (pt) | método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica | |
CL2019001002A1 (es) | Métodos y composiciones para inmunoterapia por tusc2. | |
CL2021002866A1 (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. | |
CO2018014229A2 (es) | Composición biopesticida para uso en prevención o minimizacion de la enfermedad de la planta | |
PE20240636A1 (es) | Combinaciones farmaceuticas para el tratamiento del cancer | |
WO2019155360A3 (en) | Pharmaceutical composition for treating bacterial and viral infections |